Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Shares Issued
Ratios

Immuneering (IMRX) Shares Issued (2021 - 2024)

Immuneering has reported Shares Issued over the past 4 years, most recently at $4.2 million for Q3 2024.

  • Quarterly results put Shares Issued at $4.2 million for Q3 2024, up 19482.25% from a year ago — trailing twelve months through Dec 2024 was $4.2 million (changed N/A YoY), and the annual figure for FY2025 was $421910.0, up 12.61%.
  • Shares Issued for Q3 2024 was $4.2 million at Immuneering, up from -$247465.0 in the prior quarter.
  • Over the last five years, Shares Issued for IMRX hit a ceiling of $4.2 million in Q3 2024 and a floor of -$437003.0 in Q4 2023.
  • Median Shares Issued over the past 4 years was $110447.5 (2022), compared with a mean of $507449.8.
  • Peak annual rise in Shares Issued hit 19482.25% in 2024, while the deepest fall reached 159.55% in 2024.
  • Immuneering's Shares Issued stood at $874498.0 in 2021, then plummeted by 125.26% to -$220895.0 in 2022, then crashed by 97.83% to -$437003.0 in 2023, then soared by 1061.09% to $4.2 million in 2024.
  • The last three reported values for Shares Issued were $4.2 million (Q3 2024), -$247465.0 (Q2 2024), and $247465.0 (Q1 2024) per Business Quant data.